专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

WO2012075051A1 PHA-PRODUCING BACTERIA 审中-公开
标题翻译： PHA生产细菌
公开(公告)号：WO2012075051A1
公开(公告)日：2012-06-07
申请号：PCT/US2011/062474
申请日：2011-11-29
申请人： MICROMIDAS, INC. , SMITH, Ryan, L. , BISSELL, John , MCGRATH, Casey
发明人： SMITH, Ryan, L. , BISSELL, John , MCGRATH, Casey
IPC分类号： C12P7/62 , C12R1/01
CPC分类号： C12R1/01 , C12P7/625
摘要： The present disclosure relates to isolated bacterial strains producing polyhydroxyalkanoate (PHA), microbial consortia including such strains, and cultures of such strains and microbial consortia. In particular, the present disclosure relates to compositions including such strains, microbial consortia, and cultures and methods of use thereof.
摘要翻译：本公开涉及产生聚羟基链烷酸酯（PHA）的分离的细菌菌株，包括这些菌株的微生物菌群以及这些菌株和微生物菌群的培养物。特别地，本公开内容涉及包括这些菌株，微生物菌群以及培养物及其使用方法的组合物。

62. 发明申请

WO2012045088A2 COMBINATORIAL DESIGN OF HIGHLY EFFICIENT HETEROLOGOUS PATHWAYS 审中-公开
标题翻译：高效率异质途径的组合设计
公开(公告)号：WO2012045088A2
公开(公告)日：2012-04-05
申请号：PCT/US2011/054650
申请日：2011-10-03
申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS , ZHAO, Huimin , KIM, Byoungjin , DU, Jing , YUAN, Yongbo , ERIKSEN, Dawn , SI, Tong
发明人： ZHAO, Huimin , KIM, Byoungjin , DU, Jing , YUAN, Yongbo , ERIKSEN, Dawn , SI, Tong
IPC分类号： C12N15/52
CPC分类号： C12P7/06 , C07K14/39 , C12N9/0006 , C12N9/1205 , C12N9/2445 , C12N15/1093 , C12N15/52 , C12N15/81 , C12P7/10 , C12Y101/01009 , C12Y101/0101 , C12Y101/01307 , C12Y207/01017 , C12Y302/01021 , Y02E50/16 , Y02E50/17
摘要： The present disclosure relates to the production of highly efficient heterologous pathways in host cells by identifying favorable enzyme and/or promoter combinations. In particular the present disclosure provides methods for assembly and selection of multi-step xylose and arabinose/xylose utilization pathways from a library of fungal enzymes. The present disclosure further provides compositions containing favorable enzyme combinations, as well as recombinant yeast expressing such combinations, and methods of use for bioconversion of pentose sugars. Also provided are compositions and methods involving favorable expression patterns identified by utilization of combinations of promoters of varying strengths. Provided herein are methods for assembly and selection of multi-step xylose, arabinose/xylose, and cellobiose utilization pathways from a library of promoters of varying strengths. The present disclosure further provides compositions containing heterologous enzyme-coding polynucleotides under the control of favorable promoters, as well as recombinant yeast expressing such enzymes, and methods of their use for bioconversion of pentose and/or hexose sugars.
摘要翻译：本公开涉及通过鉴定有利的酶和/或启动子组合而在宿主细胞中产生高效异源途径。特别地，本公开提供了用于从真菌酶库组装和选择多步骤木糖和阿拉伯糖/木糖利用途径的方法。本公开内容进一步提供了含有有利的酶组合的组合物，以及表达这种组合的重组酵母，以及用于生物转化戊糖的方法。还提供了涉及利用不同强度的启动子组合鉴定的有利表达模式的组合物和方法。本文提供了用于从不同强度的启动子文库组装和选择多步骤木糖，阿拉伯糖/木糖和纤维二糖利用途径的方法。本发明进一步提供了在有利启动子控制下含有异源酶编码多核苷酸的组合物，以及表达这些酶的重组酵母，以及它们用于生物转化戊糖和/或己糖的方法。

63. 发明申请

WO2011050328A2 ASSESSMENT OF SOLID TUMOR BURDEN 审中-公开
标题翻译：固体肿瘤BURDEN评估
公开(公告)号：WO2011050328A2
公开(公告)日：2011-04-28
申请号：PCT/US2010/053855
申请日：2010-10-22
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , PARSA, Andrew, T. , LANIER, Lewis, L. , CRANE, Courtney
发明人： PARSA, Andrew, T. , LANIER, Lewis, L. , CRANE, Courtney
IPC分类号： G01N33/574 , C07K14/705
CPC分类号： G01N33/57492 , G01N33/57407 , G01N33/57415 , G01N33/57434 , G01N33/57438 , G01N2800/52
摘要： The present disclosure is directed toward measurement of expression of one or both of an activating Natural Killer (NK) cell receptor and its ligand(s) on peripheral blood cells as a means to assess solid tumor burden. In particular, the present disclosure provides tools for assessing cancer recurrence or risk thereof following reduction of a solid tumor, and for developing a treatment regime for a cancer patient.
摘要翻译：本公开内容旨在测量活化的天然杀伤（NK）细胞受体及其配体在外周血细胞上的一种或两种的表达，作为评估实体肿瘤负荷的手段。特别地，本公开提供了用于在减少实体瘤之后评估癌症复发或风险的工具，以及为癌症患者开发治疗方案。

64. 发明申请

WO2010129622A1 MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS 审中-公开
标题翻译： MTOR途径抑制剂治疗恶病质
公开(公告)号：WO2010129622A1
公开(公告)日：2010-11-11
申请号：PCT/US2010/033639
申请日：2010-05-04
申请人： MACUSIGHT, INC. , NIVAGGIOLI, Thierry , WEBER, David, A. , DOR, Philippe, JM , REILLY, Philip
发明人： NIVAGGIOLI, Thierry , WEBER, David, A. , DOR, Philippe, JM , REILLY, Philip
IPC分类号： A61K9/00
CPC分类号： A61K31/573 , A61K9/0048 , A61K9/0051 , A61K31/436 , A61K31/506 , A61K31/519
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.
摘要翻译：包括但不限于眼睛中的组织的组织的疾病和病症可被有效地治疗，预防，抑制，发作延迟或归因于对这些组织施用治疗剂。本文描述的是眼科制剂，其向受试者递送多种治疗剂，包括但不限于雷帕霉素（西罗莫司），其类似物（rapalogs）或其他mTOR抑制剂）延长的时间段。眼用制剂可以放置在受试者的水性介质中，包括但不限于眼内或眼周内给药，或放置在受试者待接受治疗的疾病或病症的位置附近。可以使用一种治疗剂来治疗或预防受试者中年龄相关性黄斑变性，黄斑水肿，糖尿病性视网膜病变，葡萄膜炎，干眼症或高渗透性疾病的方法。

65. 发明申请

WO2009140659A3 TREATING DYSPNEA ASSOCIATED WITH ACUTE HEART FAILURE WITH RELAXIN 审中-公开
公开(公告)号：WO2009140659A3
公开(公告)日：2009-11-19
申请号：PCT/US2009/044249
申请日：2009-05-15
申请人： CORTHERA, INC. , UNEMORI, Elaine , TEICHMAN, Sam, L. , COTTER, Gad , STEWART, Dennis, R. , WHITEHOUSE, Martha, Jo
发明人： UNEMORI, Elaine , TEICHMAN, Sam, L. , COTTER, Gad , STEWART, Dennis, R. , WHITEHOUSE, Martha, Jo
IPC分类号： A61K38/22 , C07K14/64 , A61P9/04
摘要： The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.

66. 发明申请

WO2009140433A1 METHOD OF PROMOTING WOUND HEALING 审中-公开
标题翻译：促进愈合的方法
公开(公告)号：WO2009140433A1
公开(公告)日：2009-11-19
申请号：PCT/US2009/043854
申请日：2009-05-13
申请人： CORTHERA, INC. , STEWART, Dennis, R.
发明人： STEWART, Dennis, R.
IPC分类号： A61K38/43
CPC分类号： A61K38/2221 , A61K8/64 , A61Q19/00 , A61Q19/08
摘要： The present disclosure relates to methods of administering relaxin to promote wound healing and reduce scar formation. The disclosure further contemplates the use of relaxin in reconstructive and plastic surgery.
摘要翻译：本公开涉及施用松弛素以促进伤口愈合并减少瘢痕形成的方法。本公开进一步考虑了在重建和整形手术中使用松弛素。

67. 发明申请

WO2009134942A1 ASSAY FOR PATHOGENIC CONFORMERS 审中-公开
标题翻译：病原性制剂的测定
公开(公告)号：WO2009134942A1
公开(公告)日：2009-11-05
申请号：PCT/US2009/042185
申请日：2009-04-29
申请人： NOVARTIS AG. , PERETZ, David , WANG, Xuemei , GAO, Man (Carol) , YAM, Alice , LAU, Anthony , WU, Ping
发明人： PERETZ, David , WANG, Xuemei , GAO, Man (Carol) , YAM, Alice , LAU, Anthony , WU, Ping
IPC分类号： A61K38/00 , G01N33/53
CPC分类号： G01N33/6896 , G01N2333/4709 , G01N2800/2821
摘要： The invention provides methods for detecting the presence of a non-prion pathogenic conformer in a sample by contacting the sample suspected of containing a non-prion pathogenic conformer with a pathogenic conformer- specific binding reagent under conditions that allow the binding of the reagent to the pathogenic conformer, if present; and detecting the presence the pathogenic conformer, if any, in the sample by its binding to the reagent; where the pathogenic conformer- specific binding reagent is typically derived from a prion protein fragment and interacts preferentially with a pathogenic prion protein. Methods for diagnosis of conformational diseases are also provided.
摘要翻译：本发明提供了通过在怀疑含有非朊病毒致病性构象异构体的样品与致病性构象异构体特异性结合试剂的接触的条件下，将样品中的非朊病毒致病性构象异构体存在的方法，致病性构象异构体，如果存在; 并通过其与试剂的结合来检测样品中致病性构象异构体（如果有的话）的存在; 其中致病性构象异构体特异性结合试剂通常衍生自朊病毒蛋白片段并优先与致病性朊病毒蛋白相互作用。还提供了构象疾病诊断方法。

68. 发明申请

WO2008089454A1 METHODS FOR IMPROVING LITHIUM ION BATTERY SAFETY 审中-公开
标题翻译：改进锂离子电池安全的方法
公开(公告)号：WO2008089454A1
公开(公告)日：2008-07-24
申请号：PCT/US2008/051509
申请日：2008-01-18
申请人： ALTAIR NANOTECHNOLOGIES, INC. , HOUSE, Evan
发明人： HOUSE, Evan
IPC分类号： H01M4/02 , H01M4/48 , H01M10/40 , H01M10/42
CPC分类号： H01M4/661 , B82Y30/00 , H01M4/485 , H01M4/525 , H01M10/0525 , H01M10/42 , H01M10/443 , H01M2200/00 , Y02T10/7011
摘要： The method described herein include, a step of powering an electronic device with a lithium ion cell that has a cathode and an anode. The anode is made, a least in part, of nano-crystalline Li 4 Ti 5 O 12 .The lithium ion cell is charged. The lithium ion cell is discharged to power the electronic device. The charging and discharging can take place within a temperature range between 130°C and 250°C or between -50°C and 5°C and voltage range between 1.5 V and 4.2 V or between 2 V and 4.2 V, and will results in a safety coefficient greater than 100 or between 1000 and 20.000. The apparatus described herein comprises the lithium ion cell which is used for the aforementioned methods.
摘要翻译：本文所述的方法包括：利用具有阴极和阳极的锂离子电池为电子设备供电的步骤。阳极至少部分地由纳米晶体Li 4 N 5 O 12 12制成。锂离子电池被充电。锂离子电池被放电以为电子设备供电。充放电可以在130°C至250°C或-50°C至5°C之间的温度范围和1.5 V至4.2 V之间或2 V至4.2 V之间的电压范围内进行，并将导致安全系数大于100或介于1000与20.000之间。本文所述的装置包括用于上述方法的锂离子电池。

69. 发明申请

WO2008080126A3 TWO BIOMARKERS FOR DIAGNOSIS AND MONITORING OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE 审中-公开
公开(公告)号：WO2008080126A3
公开(公告)日：2008-07-03
申请号：PCT/US2007/088707
申请日：2007-12-21
申请人： AVIIR, INC. , TABIBIAZAR, Raymond , HYTOPOULOS, Evangelos
发明人： TABIBIAZAR, Raymond , HYTOPOULOS, Evangelos
IPC分类号： G01N33/48
摘要： The present invention identifies two circulating proteins that have been newly identified as being differentially expressed in atherosclerosis. Circulating levels of these two proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

70. 发明申请

WO2008021021A2 PLANTS WITH ENHANCED SIZE AND GROWTH RATE 审中-公开
标题翻译：具有增强尺寸和增长率的植物
公开(公告)号：WO2008021021A2
公开(公告)日：2008-02-21
申请号：PCT/US2007/017321
申请日：2007-08-03
申请人： MENDEL BIOTECHNOLOGY, INC. , RATCLIFFE, Oliver, J. , REPETTI, Peter, P. , GUTTERSON, Neal, I. , CREELMAN, Robert, A.
发明人： RATCLIFFE, Oliver, J. , REPETTI, Peter, P. , GUTTERSON, Neal, I. , CREELMAN, Robert, A.
IPC分类号： A01H5/00
CPC分类号： C12N15/8261 , A01H1/02 , C07K14/415 , C12N15/8262 , Y02A40/146
摘要： Polynucleotides and polypeptides incorporated into expression vectors have been introduced into plants and were ectopically expressed. The polypeptides of the invention regulate transcription in these plants and have been shown to confer at least one regulatory activity that results in increased size, biomass, growth rate, and/or yield as compared to a control plan.
摘要翻译：掺入表达载体的多核苷酸和多肽已经被引入植物中并被异位表达。本发明的多肽在这些植物中调节转录，并且与对照计划相比，已经表明赋予至少一种导致大小，生物量，生长速率和/或产量增加的调节活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式